Besivance Ophthalmic Solution

Besivance Ophthalmic Solution 0.6 % is a medicine used to treat the symptoms of Bacterial Conjunctivitis (pink eye), which is a condition where part of your eye is inflamed possibly due to bacteria. Besivance may be used alone or with other medications. Besivance belongs to a class of drugs called Quinolones, Ophthalmic. Besivance Ophthalmic Solution 0.6 % kills certain types of bacteria by disrupting their ability to create and repair their DNA. Besivance may not be appropriate for the infection listed above, depending on which germs are causing the infection. Bacteria in some locations may have developed resistance to Besivance, which will make it not work as well.

Product dosage: 5 ml
Package (num)	Per flacon	Price	Buy
2	$22.50	$45.00 (0%)	🛒 Add to cart
3	$19.67	$67.50 $59.00 (13%)	🛒 Add to cart
4	$19.25	$90.00 $77.00 (14%)	🛒 Add to cart
5	$17.60 Best per flacon	$112.50 $88.00 (22%)	🛒 Add to cart
Synonyms Besivance Besifloxacin Besifloxacin HCl Besifloxacin hydrochloride Besifloxacin ophthalmic

Besivance (besifloxacin ophthalmic suspension) 0.6% is a prescription fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis. It is formulated specifically for topical ophthalmic use, offering broad-spectrum in vitro activity against a wide range of gram-positive and gram-negative ocular pathogens, including key resistant strains. Its bespoke suspension delivery and benzalkonium chloride-free formulation are designed to enhance ocular surface retention and patient comfort, making it a valuable option in the ophthalmologist’s armamentarium against bacterial eye infections.

Features

• Active Ingredient: Besifloxacin 0.6% (6 mg/mL)
• Pharmaceutical Form: Sterile, preserved ophthalmic suspension
• Preservative: No benzalkonium chloride; stabilized with edetate disodium
• pH: Approximately 6.8 (close to natural tear pH)
• Viscosity: Optimized suspension to prolong corneal contact time
• Packaging: 5 mL low-density polyethylene bottle with controlled dropper tip

Benefits

• Demonstrates potent bactericidal activity against common and resistant ocular pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Strendotococcus pneumoniae
• Formulated without benzalkonium chloride, reducing potential for corneal epithelial toxicity and discomfort upon instillation
• Suspension formulation enhances drug residence time on the ocular surface, potentially improving bioavailability and clinical efficacy
• Convenient twice-daily dosing supports patient adherence to the treatment regimen
• Shown in clinical trials to achieve significantly higher rates of clinical resolution and microbial eradication compared to vehicle at day 5
• Low systemic absorption minimizes risk of systemic adverse effects

Common use

Besivance is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella catarrhalis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius. It is intended for topical ophthalmic use only and should not be injected or used systemically.

Dosage and direction

• Instill one drop into the affected eye(s) twice daily, approximately 8 to 12 hours apart, for 7 days.
• Wash hands thoroughly before use.
• Avoid touching the dropper tip to any surface, including the eye, to prevent contamination.
• If more than one topical ophthalmic drug is being used, administer them at least 5 minutes apart.
• Shake the bottle well before each use.
• Even if symptoms improve, complete the full course of therapy to prevent recurrence and resistance.

Precautions

• For topical ophthalmic use only. Not for injection or oral use.
• As with other antibacterial preparations, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute appropriate therapy.
• Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
• Contains edetate disodium, which may chelate zinc; prolonged use in zinc-deficient patients should be avoided.
• Should be used with caution in patients with a history of hypersensitivity to fluoroquinolones.
• If irritation, pain, redness, itching, or swelling worsens, the patient should discontinue use and consult a physician.

Contraindications

Besivance is contraindicated in patients with a history of hypersensitivity to besifloxacin, to other quinolones, or to any of the components in this medication.

Possible side effect

The most commonly reported ocular adverse reactions in 2-5% of patients included:

• Blurred vision (usually transient)
• Eye pain
• Eye irritation
• Eye redness
• Headache Less common ocular side effects (<2%) may include:
• Conjunctival hemorrhage
• Dry eye
• Eye pruritus
• Foreign body sensation
• Increased lacrimation
• Ocular hyperemia Non-ocular side effects were infrequent.

Drug interaction

Formal drug interaction studies have not been conducted with Besivance. However, due to minimal systemic absorption following topical ocular administration, interactions with systemically administered drugs are unlikely. When using multiple topical ophthalmic preparations, administer at least 5 minutes apart to prevent washout and potential interactions.

Missed dose

If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not instill a double dose to make up for a missed one.

Overdose

Topical ocular overdose is unlikely to cause significant systemic effects due to minimal absorption. If accidentally ingested, symptomatic and supportive care should be provided. Ocular overdose may be flushed from the eye(s) with warm tap water.

Storage

• Store at 2°C to 25°C (36°F to 77°F).
• Keep the bottle tightly closed when not in use.
• Protect from light.
• Discard any unused suspension 28 days after opening the bottle.
• Keep out of reach of children.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Besivance is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Patients should consult their ophthalmologist or physician for diagnosis and appropriate treatment recommendations. The full prescribing information should be consulted before initiating therapy.

Reviews

In multicenter, randomized, double-masked, vehicle-controlled clinical studies, Besivance demonstrated superior clinical resolution rates compared to vehicle at day 5 (45% vs 33%, p<0.001) and day 8 (84% vs 68%, p<0.001). Microbial eradication rates were also significantly higher for Besivance versus vehicle at both day 5 (91% vs 60%, p<0.001) and day 8 (88% vs 71%, p<0.001). The medication was generally well tolerated, with most adverse events being mild and transient. Many ophthalmologists note its particular value in cases where resistant organisms are suspected or in patients who have failed previous antimicrobial therapies.